ClinicalTrials.gg
RecruitingNCT07879755Updated Oct 19, 2026

An Extension Trial of GW 906 in Participants With Essential Hypertension

An interventional study of GW906 in Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
40th of 306
1,500 · median 255
Started
2026
with 36 others
No phase
144 of 408
55 open now
Primary completion
2029-01
later than 129 of 145 live
Registered
401st of 408
by date
Lead sponsor
9 of 408
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 408 studies in Hypertension with a site in China, this one is the 40th largest by planned enrollment of the 306 interventional ones that give a count, is one of 37 that started in 2026, is one of 144 with no phase, reaches primary completion later than 129 of the 145 other live ones, and was the 401st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

117 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906

Read the detailed description

This is an open-label, multicenter, non-randomized, long term extension study. Total study duration is expected to be up to 2 years, with a maximum of 3 years. Participants who have completed the previous GW906 Injection study will be assessed for eligibility at the screening visit of this study. Those who meet the eligibility criteria will receive the first dose of the extension treatment. Participants enrolled in this study will be preferentially assigned to Cohort 1. After enrollment into Cohort 2 has been initiated, participants will be assigned to receive treatment of the Cohort 2.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • siRNA
  • GW906
  • SAL0132
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed study treatment and the study in accordance with the protocol for GW906 injection.
  • Willing to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension.
  • Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection.
  • (ALT) or aspartate aminotransferase (AST) >2.5× (ULN); Total > 1.5 × ULN; (INR) > 2.0; Serum potassium > 5.0 mmol/L or \< 3.5 mmol/L; ≤30 mL/min/1.73m\^2.
  • History of any cardiovascular event within 6 months.
  • Patients with active or a history of malignancy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    GW906

    Subcutaneous injection. Expected to be up to 2 years

    Drug: GW906

Interventions

  • DrugGW906

    Subcutaneous injection. Expected to be up to 2 years

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation

    An adverse event (AE) is any untoward medical occurrence in a participant administered with investigational medicinal product, which may manifest as signs, symptoms, disease, or abnormal laboratory findings

    Time frame: every 3 month, up to 3 years

Secondary outcomes

  1. Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit

    Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit

    Time frame: Baseline, Weeks 4, 12, 24, up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 31 months is close to that.

Counting every sponsor, half of 1,500 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 19, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07879755
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Jun 12, 2026
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Jiguang Wang, Professor
Contact
jiguangwang@rjh.com.cn
+86-13764189476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GW906

Start the discussion